ClinicalTrials.gg
RecruitingNCT07525713Updated Jun 16, 2026

Virtual Reality Mirror Therapy With Focused Object-Directed Attention System

An interventional study of task-oriented training in Stroke, Rehabilitation and Virtual Reality, sponsored by National Cheng-Kung University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by National Cheng-Kung University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Stroke by National Cheng-Kung University Hospital — 6 open to participants now, 6 under way, 1 of them phase 3. Stroke · National Cheng-Kung University Hospital.

Planned enrollment
5th of 17
54 · median 39
Started
2026
with 1 other
No phase
15 of 19
3 open now
Registered
18th of 19
by date

Among the 19 studies in Stroke by National Cheng-Kung University Hospital, this one is the 5th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2026, is one of 15 with no phase, and was the 18th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

6 of the 19 studies in Stroke by National Cheng-Kung University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Stroke by National Cheng-Kung University Hospital, or all of them as a file.
02

Study summary

In this study, the investigators hypothesized that Virtual Reality Mirror Therapy with Focused Object-Directed Attention (VRMTFOA) would yield superior therapeutic effects compared to conventional Virtual Reality Mirror Therapy (VRMT) in individuals with unilateral stroke.

The aim of this study is to compare the immediate effects of a single session of VRMT, VRMTFOA, and VRMTFOA with auditory feedback on upper extremity function and brain activity in stroke patients.

03

Conditions studied

  • Stroke
  • Rehabilitation
  • Virtual Reality
  • Mirror Movement Therapy
  • Attention
  • Task Performance

Browse trials for

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of stroke with unilateral side involved;
  • A score of greater than 24 for proving higher mental function;
  • Time of onset > 6 months before treatment begins;
  • Premorbid right-handedness.

Exclusion criteria

Exclusion Criteria:

  • Severe vision impairment;
  • Major cognitive-perceptual deficit;
  • Other brain disease.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
54 participants (estimated)

Study arms

  • Active comparator
    Virtual Reality Mirror Therapy Group

    30 minutes of Virtual Reality Mirror Therapy combined with 20 minutes of conventional task-oriented therapy.

    Other: task-oriented training

  • Experimental
    Virtual Reality Mirror Therapy with Focused Object-Directed Attention (VRMTFOA)

    30 minutes of Virtual Reality Mirror Therapy with Focused Object-Directed Attention combined with 20 minutes of conventional task-oriented therapy.

    Other: task-oriented training

  • Active comparator
    VRMTFOA with auditory feedback

    30 minutes of VRMTFOA with auditory feedback combined with 20 minutes of conventional task-oriented therapy.

    Other: task-oriented training

Interventions

  • Othertask-oriented training

    Virtual Reality Mirror Therapy combined with Motor training targeted to goals that are relevant to the functional needs of the patient

06

What researchers measure

Primary outcomes

  1. Change in the result of Fugl-Meyer assessment (FMA) for motor function of upper extremity test

    Each item is rated on a three-point ordinal scale (2 points for the detail being performed completely, 1 point for the detail being performed partially, and 0 for the detail not being performed). The maximum motor performance score is 66 points for the upper extremity.

    Time frame: baseline, 9 weeks and 21 weeks

Secondary outcomes

  1. Change in the result of Modified Ashworth scale (MAS)

    Muscle tone is defined by assess muscle tone by evaluating resistance to passive stretch, reflecting the level of spasticity, with scores ranging from 0 (no increase in tone) to 4 (rigidity in flexion or extension).

    Time frame: baseline, 9 weeks and 21 weeks

  2. Change in the result of Box and blocks test

    The score is the number of blocks carried from one box to the other in one minute. Higher values represent a better outcome.

    Time frame: baseline, 9 weeks and 21 weeks

  3. Change in the result of Semmes-Weinstein monofilament (SWM) test

    The Semmes-Weinstein monofilamenttest examines the cutaneous pressure threshold, range from 1.65-6.65. Higher values represent a worse outcome.

    Time frame: baseline, 9 weeks and 21 weeks

  4. Change in the result of Motor Activity Log

    Semi-structured interview examine how much and how well the subject uses their more-affected arm for 30 ADLs. Score range from 0-5. Higher values represent a better outcome.

    Time frame: baseline, 9 weeks and 21 weeks

  5. Surface electromyography (sEMG)

    Change in the root mean square (RMS) of the EMG signal was computed to quantify the change of muscle activation.

    Time frame: baseline, 9 weeks

  6. Clinical Global Impression (CGI) scale

    Assess overall clinical change, rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: 9 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 20 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2026
First posted
Apr 13, 2026
StartActual
Apr 20, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07525713
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Apr 20, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 16, 2026

Study contacts

Hsiu-Yun Hsu, Ph.D
Contact
hyhsu@mail.ncku.edu.tw
886-6-2353535 ext. 2669

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion